Heart Diseases Cies Search Engine [selected websites]

Friday, April 20, 2012

Quantum Genomics : initiation of a First-in-Human clinical study with QGC001, its lead compound for the treatment of hypertension

Quantum Genomics
April 13th 2012 - Quantum Genomics (NYSE Euronext Paris : MLQGC), following the approval from the French Agency for Safety of Health Products (AFSSAPS), announces the initiation of a phase I clinical study in healthy volunteers with its product QGC001. QGC001 is the first of a new class of drugs that is able to monitor high blood pressure by inhibiting the aminopeptidase A enzyme (APA) at the brain level.

Arterial hypertension affects an estimated 1 billion people worldwide (13 million people in France). Despite the availability of many antihypertensive drugs, 30% to 60% of patients diagnosed with hypertension do not have their blood pressure properly controlled by current medications for various reasons (49% in France ([1])). Moreover, the overall incidence of resistant hypertension to at least three antihypertensive drugs (including a diuretic) is estimatedaround 8% to 12% of the hypertensive population... Quantum Genomics' Press Release -

Tuesday, April 3, 2012

HeartWare International Expands Intellectual Property and Technology Portfolio Through Definitive Agreement to Acquire World Heart Corporation for US$8 Million

HeartWare International
March 29, 2012 - HeartWare International, Inc. (Nasdaq:HTWR) (ASX:HIN), which develops and manufactures miniaturized ventricular assist devices, and World Heart Corporation (Nasdaq:WHRT), which has been engaged in the development of left ventricular assist devices, announced that they have entered into a definitive merger agreement under which HeartWare will acquire WorldHeart for consideration of US$8 million, which will be paid in shares of HeartWare common stock or cash, at HeartWare's election.

WorldHeart Corporation

"WorldHeart has been an important participant in the development of ventricular assist therapies for many years and has amassed over one hundred patents and patent applications. In line with our goal to be a leader in the VAD market for years to come, we believe that bolstering our patent portfolio and adding WorldHeart's technologies broadens our options for the future," said Doug Godshall, President and CEO of HeartWare. "While we are intensely focused on the FDA panel for our HVAD® System next month, and commencement of first-in-man studies for our MVAD® System mid-year, we look forward to integrating WorldHeart's technologies and members of its talented team into our research efforts."... HeartWare International's Press ReleaseWorldHeart Corporation's Press Release  -